ONT-10

Cascadian Therapeutics Inc. · Phase 1 active Biologic

At a glance

Generic name	ONT-10
Sponsor	Cascadian Therapeutics Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors (PHASE1)
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer (PHASE1)
Phase 1 Study of ONT-10 in Patients With Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ONT-10 CI brief — competitive landscape report
ONT-10 updates RSS · CI watch RSS
Cascadian Therapeutics Inc. portfolio CI